Regeneron Pharmaceuticals, Inc. (REGN)

NASDAQ: REGN · Real-Time Price · USD
509.72
-3.86 (-0.75%)
At close: Jun 20, 2025, 4:00 PM
511.05
+1.33 (0.26%)
After-hours: Jun 20, 2025, 7:03 PM EDT
-0.75%
Market Cap 53.86B
Revenue (ttm) 14.09B
Net Income (ttm) 4.50B
Shares Out 105.67M
EPS (ttm) 39.43
PE Ratio 12.93
Forward PE 14.08
Dividend $1.76 (0.35%)
Ex-Dividend Date May 20, 2025
Volume 2,244,569
Open 521.05
Previous Close 513.58
Day's Range 506.38 - 521.31
52-Week Range 476.49 - 1,211.20
Beta 0.31
Analysts Buy
Price Target 854.26 (+67.59%)
Earnings Date Jul 31, 2025

About REGN

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 2, 1991
Employees 15,106
Stock Exchange NASDAQ
Ticker Symbol REGN
Full Company Profile

Financial Performance

In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.

Financial Statements

Analyst Forecast

According to 23 analysts, the average rating for REGN stock is "Buy." The 12-month stock price forecast is $854.26, which is an increase of 67.59% from the latest price.

Price Target
$854.26
(67.59% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease

The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the elderly and is characterized by itchiness, blisters and lesions.

Other symbols: SNY
1 day ago - WSJ

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP

1 day ago - GlobeNewsWire

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in sustained disease remission and reductions...

Other symbols: SNY
1 day ago - GlobeNewsWire

Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

4 days ago - Reuters

Former 23andMe CEO Anne Wojcicki wins bid for control of her former company, topping Regeneron

Anne Wojcicki, former chief executive of 23andMe, won a bid to acquire the genetic testing company she founded in a second auction.

5 days ago - CNBC Television

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respirator...

Other symbols: SNY
6 days ago - GlobeNewsWire

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

6 days ago - GlobeNewsWire

Regeneron CEO on 23andMe bid: Trying to balance individual privacy with biotech & genetics research

Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, privacy concerns over 23andMe's genetic data, importance of biotechnology, and mo...

10 days ago - CNBC Television

Regeneron Pharma Shares Rise Over 3% After Key Signal

REGN climbs over 16 points after the alert

11 days ago - Benzinga

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference Transcript

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ET Company Participants Christopher R. Fenimore - Executive VP of Finance & ...

12 days ago - Seeking Alpha

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than...

13 days ago - GlobeNewsWire

Why Regeneron Is Falling And Why You Should Avoid It

Regeneron Pharmaceuticals (REGN) has been in a persistent downtrend for over 280 days. The stock is currently in the 10th Phase of its 18-Phase Adhishthana Cycle, our proprietary cyclical framework.

17 days ago - Benzinga

REGN Stock Undervalued At $500?

Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease (COPD) ...

19 days ago - Forbes

Regeneron's weight-loss drug helps preserve muscle mass in study

Regeneron Pharmaceuticals said on Monday its experimental weight-loss drug combination helped preserve muscle mass in a mid-stage study.

19 days ago - Reuters

Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China

19 days ago - GlobeNewsWire

Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing

Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p

21 days ago - GlobeNewsWire

S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet

Major U.S. equities indexes were mixed in the final session of the holiday-shortened trading week as President Donald Trump reverted to an antagonistic tone on trade with China and the latest Personal...

Other symbols: ULTA
21 days ago - Investopedia

Regeneron dashes Wall Street's hopes as COPD treatment trial suffers a failure

Regeneron's stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.

21 days ago - Market Watch

Itepekimab Failure A Setback For Sanofi And Regeneron

Itepekimab's inconsistent phase 3 results represent a setback for Regeneron Pharmaceuticals and Sanofi. The results do not support regulatory submissions and a 3-4 year approval delay, and lower peak ...

Other symbols: SNY
21 days ago - Seeking Alpha

Top Stock Movers Now: Regeneron, Ulta Beauty, Cooper, and More

U.S. equities were lower at midday as the market focused on the future of U.S.-China trade. The Dow Jones Industrial Average, S&P 500, and Nasdaq all lost ground.

Other symbols: COOULTA
22 days ago - Investopedia

Regeneron stock crashes on COPD data: here's why I'm buying REGN today

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) crashed more than 15% this morning on disappointing data from Phase 3 trials of its experimental drug itepekimab. Itepekimab is a drug candidate for chroni...

22 days ago - Invezz

Elastic, Gap, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Friday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Friday.

Other symbols: ESTCGAP
22 days ago - Benzinga

Regeneron shares slide on mixed trial data on smoker's lung drug

Regeneron shares fell nearly 13% before the bell on Friday after its experimental drug for patients with a type of lung condition commonly called "smoker's lung" failed a late-stage trial, although it...

22 days ago - Reuters

Sanofi, Regeneron's Itepekimab Delivers Mixed Results in Late-Stage Trials

Sanofi and Regeneron said that drug candidate Itepekimab didn't meet primary endpoint in a phase three study, although a benefit was seen earlier in the trial.

Other symbols: SNY
22 days ago - WSJ

Mary Kay Inc. Awards 10 Grants to Young Innovators at 2025 Regeneron International Science and Engineering Fair

DALLAS--(BUSINESS WIRE)-- #MaryKay--Mary Kay Inc., a global advocate for furthering young women's education and encouraging youth to follow their STEM dreams, returned for a second year as a Special A...

23 days ago - Business Wire